A neurocognitive disorder (NCD) is a condition in which the brain’s ability to think, remember, reason, or pay attention declines enough to be noticeable and measurable. It replaced the older term “dementia” in the diagnostic manual used by mental health professionals, and it covers a broader range of causes and severity levels than dementia traditionally implied. The category includes everything from mild memory slips that don’t interfere with daily life to severe cognitive loss that makes independent living impossible.
Why the Term Replaced “Dementia”
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) retired “dementia” as a formal diagnosis and replaced it with “major neurocognitive disorder.” The change wasn’t just cosmetic. The word dementia carried two misleading assumptions: that cognitive decline only affects older people, and that it’s almost always Alzheimer’s disease. Neither is true. Traumatic brain injuries, HIV, chronic alcohol use, and several other conditions can cause significant cognitive decline in people well under 65.
The DSM-5 also introduced a second, milder category called “mild neurocognitive disorder,” roughly equivalent to what clinicians previously called mild cognitive impairment (MCI). This two-tier system gives clinicians a way to identify and monitor people in the earlier stages of decline, before they lose the ability to manage daily tasks on their own.
Mild vs. Major: How the Two Levels Differ
The core distinction is functional independence. In mild neurocognitive disorder, cognitive abilities have declined noticeably compared to a person’s previous baseline, but they can still handle everyday responsibilities like paying bills, managing medications, and driving. They may need to use more compensatory strategies, like writing lists or setting reminders, but they get by.
Major neurocognitive disorder means cognition has declined enough to interfere with the ability to function independently. A person might struggle to follow a conversation, get lost in familiar places, or be unable to manage finances without help. To qualify for a diagnosis, decline must be documented in at least one cognitive domain and must represent a clear change from the person’s prior abilities. It also can’t be explained by a temporary episode of confusion (delirium) or a psychiatric condition like depression alone.
The Cognitive Domains Affected
Clinicians evaluate decline across several specific cognitive domains. A person doesn’t need to show problems in all of them. Significant decline in even one domain, combined with functional impairment, is enough for a major NCD diagnosis.
- Learning and memory: difficulty retaining new information, repeating questions, forgetting recent events
- Complex attention: trouble concentrating, being easily distracted, losing track in environments with multiple stimuli
- Executive function: problems with planning, decision-making, multitasking, or adjusting behavior when rules change
- Language: difficulty finding words, following conversations, or understanding written material
- Perceptual-motor ability: trouble with spatial awareness, navigating familiar routes, or coordinating movements with what the eyes see
- Social cognition: difficulty reading emotions, recognizing social cues, or behaving appropriately in social situations
One important shift in the DSM-5 framework is that memory no longer holds a privileged position. Under the old definition of dementia, memory loss was essentially required. Now, a person could be diagnosed based on declining executive function or language alone, which better captures conditions like frontotemporal degeneration, where personality and behavior changes often appear before any memory problems.
What Causes Neurocognitive Disorders
Neurocognitive disorder is an umbrella diagnosis. Once a clinician confirms that cognitive decline is present, the next step is identifying the underlying cause. The DSM-5 lists more than a dozen potential etiologies:
- Alzheimer’s disease: the most common cause, with a slow, insidious onset. Memory and learning are typically affected first, with other domains following. An estimated 7.2 million Americans age 65 and older are living with Alzheimer’s dementia in 2025.
- Vascular disease: caused by reduced blood flow to the brain, often from strokes or small vessel disease. Onset can be abrupt, and decline sometimes follows a stepwise pattern rather than a gradual slope.
- Lewy body disease: marked by fluctuations in alertness and attention, visual hallucinations, and movement symptoms similar to Parkinson’s disease. Cognitive decline and motor problems tend to emerge around the same time.
- Frontotemporal degeneration: typically begins before age 65 with changes in personality, social behavior, or language rather than memory loss.
- Traumatic brain injury: a single severe injury or repeated head impacts can cause lasting cognitive deficits, particularly in attention and executive function.
- Substance or medication use: long-term heavy alcohol use is the most common culprit, but certain medications and recreational drugs can also cause lasting cognitive damage.
- HIV infection, Parkinson’s disease, Huntington’s disease, and prion disease round out the major recognized causes.
Some people have more than one cause contributing simultaneously. A person with early Alzheimer’s changes and a history of small strokes, for example, would receive a diagnosis specifying multiple etiologies.
How It’s Diagnosed
Diagnosis typically begins with a clinical interview and cognitive screening, then moves to more formal neuropsychological testing when the results are ambiguous or a baseline measurement is needed. Neuropsychological assessment uses a battery of standardized tests covering memory, attention, processing speed, reasoning, spatial skills, and language. A person’s scores are compared against norms for their age, education, and demographic background.
In Alzheimer’s-related decline, memory performance at the time of diagnosis is roughly 3 standard deviations below that of similar healthy adults, a substantial gap. A clinically meaningful difference between any two cognitive abilities is about half a standard deviation, which translates to roughly 7 IQ-scale points.
Brain imaging plays a supporting role. Structural MRI can detect tissue loss, and in Alzheimer’s disease the hippocampus (a structure critical for forming new memories) shows roughly 20% volume loss even at a mild stage. The temporal, parietal, and prefrontal regions of the brain are also commonly affected. PET scans can detect reduced brain metabolism in regions involved in memory, or directly visualize the buildup of abnormal proteins associated with Alzheimer’s. These imaging tools help clinicians distinguish between different underlying causes and rule out treatable conditions like brain tumors or fluid buildup.
How Many People Are Affected
The numbers are large and growing. In the United States alone, about 7.2 million people age 65 and older have Alzheimer’s dementia in 2025. The risk rises steeply with age: 5.1% of people aged 65 to 74 have Alzheimer’s, compared to 33.4% of those 85 and older. Roughly 200,000 Americans under age 65 are living with younger-onset dementia.
Mild neurocognitive disorder is even more prevalent. An estimated 5 to 7 million older Americans, roughly 8% to 11% of the population over 65, may have mild cognitive impairment related to Alzheimer’s disease. Not all of them will progress to major NCD, but a significant portion will. In one large study with about five years of follow-up, 28.7% of people with mild cognitive impairment progressed to dementia. The cumulative incidence was 5.4% at one year and 42.5% at five years. Even among the 38% who initially reverted to normal cognition, nearly two-thirds later developed cognitive impairment or dementia again.
Risk Factors You Can Change
Several modifiable risk factors are linked to cognitive decline. The CDC has identified eight that stand out: high blood pressure, physical inactivity, obesity, diabetes, depression, cigarette smoking, hearing loss, and binge drinking. Each one individually raises the likelihood of cognitive problems, and they compound. Among adults with no risk factors, only 3.9% reported subjective cognitive decline. Among those with four or more risk factors, that figure jumped to 25%.
Depression and hearing loss showed particularly strong associations, with 28.5% and 24.7% of affected adults reporting cognitive decline, respectively. Hearing loss is worth noting because it’s both common and treatable, yet often goes unaddressed for years. Correcting it with hearing aids may reduce cognitive load and help maintain social engagement, both of which matter for long-term brain health.
Treatment and Management
There is no cure for most neurocognitive disorders, but treatments can slow progression or manage symptoms depending on the underlying cause. For Alzheimer’s disease specifically, cholinesterase inhibitors boost levels of a brain chemical involved in memory and judgment. These medications are also sometimes prescribed for vascular dementia, Parkinson’s disease dementia, and Lewy body dementia.
Two newer medications, lecanemab (Leqembi) and donanemab (Kisunla), are FDA-approved for people with mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s. Unlike older drugs that manage symptoms, these target the abnormal protein buildup in the brain that drives the disease, aiming to slow the rate of decline rather than simply mask it.
Beyond medication, occupational therapy helps people adapt their homes and routines to stay safe and independent longer. Staying physically active, maintaining social connections, and finding creative outlets like painting, singing, or writing all contribute to quality of life. For symptoms like depression, sleep disruption, hallucinations, or agitation that often accompany cognitive decline, separate treatments are available and can make a meaningful difference in day-to-day comfort for both the person affected and their caregivers.